User:Mr. Ibrahem/Viloxazine

Viloxazine, sold under the brand name Qelbree among others, is a medication which is used to treat attention deficit hyperactivity disorder (ADHD). It is taken by mouth. It was used for almost 30years for depression before being discontinued due to commercial reasons. The original formulation was immediate-release while that used for ADHD in extended-release.

Side effects include trouble sleeping, headache, sleepiness, tiredness, nausea, dry mouth, constipation, irritability, increased heart rate, and increased blood pressure. Rarely, it may cause suicidal thoughts or behaviors or result in mania in people with bipolar. There is a low risk of misuse. It is a selective norepinephrine reuptake inhibitor (NRI).

Viloxazine was patented in 1969 and approved for medical use in the United Kingdom in 1974. It was not approved in the United States at this time. It was repurposed and approved in the United States in 2021. It is not a controlled substance. In the United States it costs about 325 USD per month for a dose of 200 mg per day.